Abstract: Compounds of the formula and the salts thereof with physiologically tolerated acids and the stereoisomers thereof, in which the substituents have the meanings stated in the description, are described. Also disclosed are intermediates for their preparation. The compounds are suitable for controlling diseases.

Abstract: The invention relates to a compound of the formula I: or a salt thereof with a physiologically tolerated acid, or stereoisomers thereof, wherein R1, R2, A, B, C and D have the meanings described in the specification.

Abstract: The invention relates to processes for preparing 2-aminomethyl-4-cyanothiazole and its salts of the formulae Ia and Ib in which n=1 or 2 and for n=1, X is chloride, bromide, triflate and hydrogen sulfate and for n=2, X is sulfate, which comprises the process step where the aminonitrile of the formula II is stirred with a cysteine ester of the formula III, in which R1 is branched or linear C1-10-alkyl or where n=0, 1 or 2 and R2 is branched or linear C1-C10C10-alkyl or C1-C4-alkoxy or C1-C4-dialkylamino in an inert solvent in the presence of a base at from 0° C. to 80° C. until the reaction has essentially proceeded to completion, and to the compounds of the formulae Ia and Ib.

Abstract: A process for preparing bisphenol alkoxylates comprises reacting at least one bisphenol with alkylene oxide in the presence of a phosphine catalyst which is essentially free of alkali metal hydroxide.

Abstract: Compounds of the formula 1

Abstract: The fumaric acid salt of 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol is useful for treating disorders which respond to dopamine D3 ligands. It has higher stability at low pH and is therefore particularly suitable for oral administration in pharmaceutical compositions comprising this salt.

Abstract: The invention relates to a compound of the formula I 1

Abstract: The fumaric acid salt of 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol is useful for treating disorders which respond to dopamine D3 ligands. It has higher stability at low pH and is therefore particularly suitable for oral administration in pharmaceutical compositions comprising this salt.

Abstract: Compounds of the formula and the salts thereof with physiologically tolerated acids and the stereoisomers thereof, in which the substituents have the meanings stated in the description, are described. Also disclosed are intermediates for their preparation. The compounds are suitable for controlling diseases.

Abstract: Compounds of the formula where A, B, D, R1 and R2 have the meanings stated in the description, are described. The compounds are suitable for controlling diseases. The novel compounds are prepared via compounds of the formula H2N—CH2—G—M.

Abstract: The fumaric acid salt of 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol is useful for treating disorders which respond to dopamine D3 ligands. It has higher stability at low pH and is therefore particularly suitable for oral administration in pharmaceutical compositions comprising this salt.

Abstract: A process for preparing enantiomerically pure esters of the formula I (Ia and Ib) where the substituents have the following meanings: R1 hydrogen or substituted or unsubstituted C1-C6-alkyl, C1-C6-alkoxy or Cl-C6-alkanoyl, R2 and R3 independently of one another hydrogen or substituted or unsubstituted C1-C6-alkyl, C1-C6-alkoxy, C1-C6-alkanoyl, C1-C6-alkylthio, C1-C6-alkylsulfinyl or C1-C6-alkylsulfonyl, R4 and R5 R4≠R5 and independently of one another hydrogen or substituted or unsubstituted C1-C6-alkyl or R4 and R5 form together with the carbon atoms to which they are bonded a substituted or unsubstituted C3-C6-cycloalkylidene, R6 substituted or unsubstituted aryl, C1-C20-alkyl, C3-C20-alkenyl, C3-C20-alkynyl, C1-C20-alkoxy-C1-C20-alkyl comprises converting racemic compounds of the formula II, where the substituents R1 to R5 have the abovementioned meanings, with a lipase or esterase in the presence of vinyl esters of the formula III, wher

Abstract: An improved process for the preparation of 1,2,4-triazolo[1,5-a]pyrimidine compounds comprising the reaction involving a compound of formula II and a compound of formula III in the presence of an oxidizing agent and a reducing agent, wherein a metal salt is added to form a complex with the oxidized reducing agent produced in the process, and this complex is separated from the desired product.

Abstract: Bisimides of the formula I where R1, R2, R3 and R4 have the meanings stated in the description, are prepared in a process in which the corresponding dicarboxylic anhydrides of the formulae II and III R1—CO—O—CO—R2  (II) R3—CO—O—CO—R4  (III), are reacted with an amine of the formula H2N—R—NH2 in the presence of a tertiary amine.

Abstract: Compounds of the formula ##STR1## where A, B, D, R.sup.1 and R.sup.2 have the meanings stated in the description, are described. The compounds are suitable for controlling diseases.The novel compounds are prepared via compounds of the formulaH.sub.2 N--CH.sub.

Abstract: A process for reducing the level of tri-substituted phosphine, arsine and/or stibine oxide from a mixture comprising a desired product and at least one such oxide is provided, comprising the addition of a metal salt to the mixture to form a complex with the oxide, and removing the complex from the mixture. This process has particular utility for removing triphenylphosphine oxide from a mixture--a task that was previously hard to perform.

Abstract: Thrombin inhibitors of the formula ##STR1## where R.sup.1, A, B and D have the meaning indicated in the description, and intermediates for the preparation thereof are described.The compounds I are suitable for controlling diseases.

Abstract: Compounds of the formula I ##STR1## in which R.sup.1, A and B have the meanings stated in the description, and the preparation thereof are described. The novel compounds are suitable for controlling diseases.